Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now full pipeline

Major Depression: full-pipeline trial registry

7 of 29 indexed Major Depression trials are currently recruiting.

Corpus placement: #552 of 28,707 conditions by registered trial count.

29 US clinical trials · 7 currently recruiting · #552 of 28,707 conditions by registered trial count

Major Depression: 29 US clinical trials tracked, 7 recruiting.

Major Depression is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Mental Health (NIMH), running 5 of these trials.

Enrollment posture brief

Registry condition major-depression

OPEN 7 | RECR 24% | LATE 9 | EARLY 6 | RANK #552 | SPON 5

Nearest open-share peer: Burnout, Professional (24% recruiting · 29 trials)

Advanced Breast Cancer62.1%Amyloidosis51.7%Major Depression (this)24%Arthritis, Rheumatoid17.2%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Major Depression

Major Depression lists 7 open slots (24% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Major Depression on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Major Depression is recruiting below its size-band peers.

    7 of 29 indexed trials (24.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Major Depression research.

    National Institute of Mental Health (NIMH) accounts for 5 of 29 trials (17.2%). 20 distinct sponsors appear on at least one study for this condition label.

  3. Typical Major Depression enrolment sits around 100 participants.

    Median target enrolment is 100 among the 29 trials that report a genuine target (sentinel values excluded). 14 of those (48.3%) plan for fewer than 100 participants.

  4. Major Depression research is mostly interventional.

    22 interventional and 7 observational studies make up this index (75.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31Phase 48

Open and recent trials

29 total, page 1 of 1

RECRUITING 1,260 participants

NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder

National Institute of Mental Health (NIMH)

NCT05669703

RECRUITING 1,000 participants

University of Iowa Interventional Psychiatry Service Patient Registry

Mark Niciu

NCT04480918

RECRUITING 120 participants

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

University of Southern California

NCT02434393

RECRUITING Phase 2 75 participants

Leucine in Midlife Depression

Emory University

NCT06580145

RECRUITING Phase 1 70 participants

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

National Institute of Mental Health (NIMH)

NCT03973268

RECRUITING Phase 2 60 participants

Ketamine Alcohol (in Treatment-Resistant Depression)

Mark Niciu

NCT02122562

RECRUITING NA 20 participants

Accelerated High-Dose tDCS for Depression

Medical University of South Carolina

NCT07226011

COMPLETED NA 2,443 participants

Person-Centered Versus Measurement-Based Care in Mental Health

University of Pittsburgh

NCT02507349

COMPLETED 953 participants

Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry

OM1

NCT04235725

COMPLETED 795 participants

Duke Conte Center for the Neuroscience of Depression in Late Life

Duke University

NCT00576875

COMPLETED Phase 4 627 participants

Prozac Treatment of Major Depression: Discontinuation Study

New York State Psychiatric Institute

NCT00427128

COMPLETED Phase 4 262 participants

Preventing Depression Recurrence in Diabetes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00374426

COMPLETED NA 238 participants

The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.

US Department of Veterans Affairs

NCT00466323

COMPLETED Phase 3 220 participants

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Hadassah Medical Organization

NCT00158990

COMPLETED NA 168 participants

Motivational Interviews for Depression in Primary Care

Denver Health and Hospital Authority

NCT01114334

COMPLETED NA 161 participants

Increasing Use of Mental Health Services

Weill Medical College of Cornell University

NCT00605358

COMPLETED 160 participants

Serum Markers as a Bioassay for Unipolar Depression

Steward St. Elizabeth's Medical Center of Boston

NCT00825799

COMPLETED Phase 4 153 participants

Thyroid Medication and Antidepressants for Treating Major Depression

Emory University

NCT00208702

COMPLETED Phase 4 100 participants

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

Emory University

NCT00208715

COMPLETED Phase 4 75 participants

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

Mayo Clinic

NCT03156504

COMPLETED Phase 2 39 participants

Lexapro and Pramipexole and to Treat Major Depression

National Institute of Mental Health (NIMH)

NCT00086307

COMPLETED 32 participants

Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

Massachusetts General Hospital

NCT02253225

COMPLETED NA 30 participants

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

Massachusetts General Hospital

NCT02594696

COMPLETED Phase 4 30 participants

Pharmacotherapy in Depression With Panic Spectrum

University of Pittsburgh

NCT00177996

COMPLETED NA 23 participants

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

University of Arizona

NCT02062840

COMPLETED Phase 2 22 participants

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

National Institute of Mental Health (NIMH)

NCT02484456

COMPLETED Phase 4 17 participants

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

Indiana University School of Medicine

NCT00707863

COMPLETED Phase 4 8 participants

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

Conrad, Erich J., M.D.

NCT00595699

COMPLETED Phase 1 5 participants

Antidepressant Effects of NR2B in Major Depression

National Institute of Mental Health (NIMH)

NCT00472576

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1
Phase 4 8

Named interventions

Most-linked intervention names on Major Depression records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

sertraline Drug
2 trials
Ketamine Drug
2 trials
placebo Drug
2 trials
Escitalopram Drug
2 trials
Enhanced treatment as usual (e-TAU) Behavioral
1 trials
Family Member Provider Outreach Behavioral
1 trials
Harmonized Depression Outcome Measures Other
1 trials
Triiodothyronine Drug
1 trials

US sites by state

Facility locations filed on Major Depression trials. A trial with sites in several states counts in each.

Maryland 7 trials
Pennsylvania 4 trials
Massachusetts 4 trials
New York 3 trials
Georgia 3 trials
California 3 trials
Iowa 2 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Major Depression page

29 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depression condition card totals 29 registered trials; most-linked intervention sertraline; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.